#5-34E. Breaking the Steroid Cycle: IL-6 Receptor Inhibitors vs. Conventional Synthetic Immunomodulators in Refractory PMR (RMDOpen, 2026)

How do we optimize management for polymyalgia rheumatica patients who relapse or fail glucocorticoid tapering? In this retrospective comparative cohort study using US Medicare claims data, researchers compared the real-world effectiveness and safety of interleukin-6 receptor inhibitors (IL-6Ris) against conventional synthetic immunomodulators (csIM) in patients with steroid-refractory polymyalgia rheumatica. The key clinical finding reveals that patients initiating IL-6Ri therapy were significantly more likely to discontinue glucocorticoids or achieve minimal use (two milligrams or less per day) by year one compared to those on csIM, representing a crucial steroid-sparing benefit. However, when critically appraising these results, clinicians must consider the limitations of retrospective claims data, such as potential misclassification, coding bias for off-label reimbursement, and a higher risk of primary hospitalized infections during the first year of IL-6Ri use. Ultimately, this study provides pivotal first-of-its-kind real-world comparative evidence, supporting the clinical rationale for earlier biological intervention with IL-6 receptor inhibitors to mitigate long-term corticosteroid toxicity in steroid-dependent polymyalgia rheumatica.

Citation: Anisha Bharadwaj Dua, Robert F Spiera, Ara Dikranian, et al. Effectiveness and safety of interleukin 6 receptor inhibitors versus conventional immunomodulatory therapy in steroid-refractory polymyalgia rheumatica. RMD Open. 2026. DOI: 10.1136/rmdopen-2026-006850

URL: https://doi.org/10.1136/rmdopen-2026-006850

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.